NCT05785715 2025-07-01
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie
Phase 2 Terminated
AbbVie
Viome
Hutchmed
W.L.Gore & Associates
AbbVie
PENTAX Europe GmbH
Integra LifeSciences Corporation